ArticleJournal of surgical oncology2025
Risk of Contralateral Central Compartment Recurrence Following Unilateral Therapeutic Neck Dissection for Papillary Thyroid Carcinoma.
Article in Journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
BACKGROUND AND
objectivesThe utility of bilateral central compartment neck dissection (CCND) in patients with papillary thyroid carcinoma (PTC) and unilateral clinically node-positive disease remains debatable. Previous studies evaluated contralateral occult lymph-node metastases, which do not necessarily correlate with clinical recurrences. The objective of our study was to evaluate whether unilateral CCND is sufficient, specifically evaluating recurrence in the contralateral central neck.
methodsPatients with PTC treated with total thyroidectomy and therapeutic unilateral CCND with at least 2 years of follow-up were included.
resultsA total of 118 patients had unilateral therapeutic CCND, 58% with lateral neck dissection, 63% female, mean age of 48.1 ± 16.3 years. Mean follow-up was 6.2 ± 3.9 years, tumor size 17.6 ± 12 mm, 39% had minimal extrathyroidal extension (ETE) and 4% had gross ETE. A mean of 2.6 ± 2.6 LN were involved in the central compartment (size 9.4 ± 6.5 mm) and 4.4 ± 4 involved in the lateral neck (size 24.9 ± 14.3 mm). Recurrence on the ipsilateral side was detected in 6 patients (5%), while contralateral central compartment recurrence (the primary outcome) was detected in only 1 patient (1%).
conclusionsIn patients with PTC and unilateral clinically node-positive central compartment disease, unilateral therapeutic CCND is sufficient, with only 1% risk of recurrence in the contralateral central compartment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.